36
Participants
Start Date
August 15, 2018
Primary Completion Date
December 3, 2020
Study Completion Date
February 2, 2021
Avelumab
IV treatment
Binimetinib
Oral treatment
Talazoparib
Oral treatment
Institut Jules Bordet, Brussels
UZ Gent, Ghent
UPMC Hillman Cancer Center, Pittsburgh
Horizon Oncology Research, LLC, Lafayette
Highlands Oncology Group, Fayetteville
Highlands Oncology Group, Rogers
Highlands Oncology Group, Springdale
The University of Texas MD Anderson Cancer Center, Houston
University of Colorado Denver CTO (CTRC), Aurora
University of Colorado Hospital, Aurora
University of Utah, Huntsman Cancer Hospital, Salt Lake City
University of Utah, Huntsman Cancer Institute, Salt Lake City
California Cancer Associates for Research and Excellence, Inc (cCARE), Encinitas
Singapore National Eye Centre, Singapore
Singapore General Hospital, Singapore
SingHealth Investigational Medicine Unit, Singapore
National Heart Centre Singapore, Singapore
National Cancer Centre Singapore, Singapore
Lead Sponsor
Pfizer
INDUSTRY